jiliasia

jiliasia RapidTranslate.org Centralizes Language Resources and Expands Certified Translation Services Globally

Mumbai: The Enforcement Directorate (ED) stated on Saturday that its Raipur zonal unit has issued a Provisional Attachment Order under the Prevention of Money Laundering Act (PMLA), 2002, attaching assets worth Rs 387.99 crore in connection with the ongoing Mahadev Online Book betting case. The order, issued on December 5, 2024, marks a significant escalation in the ED’s crackdown on the syndicate’s illegal financial operations. According to the ED statement, the attached assets include investments linked to one of the accused, Hari Shankar Tibrewal, through a Mauritius-based company, M/s Tano Investment Opportunities Fund. These investments, channeled via Foreign Portfolio Investment (FPI) and Foreign Direct Investment (FDI), are part of a broader financial network facilitating the betting operations. In addition to these investments, several immovable properties located in Chhattisgarh, Mumbai, and Madhya Pradesh, belonging to the syndicate's promoters and their associates, have also been seized. The ED's investigations have revealed that M/s Mahadev Online Book, an umbrella syndicate, has been running online platforms for illegal betting. The syndicate's operations include enrolling new users, creating User IDs, and laundering money through a complex web of benami bank accounts, further complicating efforts to track the illicit funds. As part of its ongoing investigation, the ED has seized and frozen assets, including cash amounting to Rs 19.36 crore and valuables worth Rs 16.68 crore. Additionally, movable assets, such as bank balances and securities, totaling Rs 1,729.17 crore, have been frozen. Earlier in the case, two Provisional Attachment Orders were issued, attaching assets worth Rs 142.86 crore. In total, the ED has seized, frozen, or attached proceeds of crime worth approximately Rs 2,295.61 crore. In a breakthrough development, ED investigators uncovered that substantial funds generated from the betting business were being funneled into the stock market through a network of dummy companies. These companies, operated by several accused and absconding associates, were reportedly used to divert Rs 423 crore into stock portfolios as of February 29, 2024. Professional entry operators helped manipulate these funds, converting them into legitimate transactions through unlisted equity dealings, masking the illicit origins of the money. So far, the ED has arrested 11 individuals in connection with the Mahadev Online Book betting case and has filed four Prosecution Complaints before the Hon’ble Special Court (PMLA) in Raipur. The investigation continues, with more arrests and seizures expected as financial probe authorities work to dismantle the syndicate’s operations and recover the illicit proceeds.Disability ministers will ‘champion’ inclusion and accessibility, says Timms

Levis throws 2 TD passes to help Titans outlast Texans 32-27OTTAWA - TikTok is challenging the federal government’s order to shut down its operations in Canada. The company filed documents in Federal Court in Vancouver last Thursday. In November, Ottawa ordered the dissolution of TikTok’s Canadian business after a national security review of the Chinese company behind the social media platform. That means TikTok must “wind down” its operations in Canada, though the app will continue to be available to Canadians. TikTok is asking the court to overturn the government’s order and to put a pause on the order going into effect while the court hears the case. It is claiming the decision was “unreasonable” and “driven by improper purposes.” This report by The Canadian Press was first published Dec. 10, 2024.NASSAU, Bahamas — Justin Thomas was long off the tee and made a few long putts on the back nine to overtake Scottie Scheffler with a 6-under 66 and build a one-shot lead Saturday over golf's best player going into the final round of the Hero World Challenge. Thomas is trying out a 46-inch driver — a little more than an inch longer than normal — that he previously used for practice at home to gain speed and length. He blasted a 361-yard drive to 8 feet on the par-4 seventh hole and led the field in driving distance. But it was a few long putts that put him ahead of Scheffler, who had a 69. Thomas was on the verge of falling two shots behind when he made an 18-foot par putt on the par-3 12th hole. On the reachable par-4 14th, he was in a nasty spot in a sandy area and could only splash it out to nearly 50 feet. He made that one for a most unlikely birdie, while behind him Scheffler muffed a chip on the 13th hole and made his lone bogey of a windy day. Scheffler never caught up to him, missing birdie chances on the reachable 14th and the par-5 15th. Thomas hit his approach to 3 feet for birdie on the 16th after a 343-yard drive. Scheffler made an 18-foot birdie putt on the 16th to close within one. Scheffler missed birdie chances on the last two holes from the 10-foot and 15-foot range, while Thomas missed an 8-foot birdie attempt at the last. "I had a stretch at 13, 14, 15 where I felt like I lost a shot or two there, but outside of that I did a lot of really good things today," Scheffler said. Thomas hasn't won since the 2022 PGA Championship at Southern Hills, and a victory at Albany Golf Club wouldn't count as an official win. But the two-time major champion has made steady progress toward getting his game back in order. "I'm driving it great. I've had a lot of confidence with it," Thomas said of his longer driver. "I feel like I've been able to put myself in some pretty good spots going into the green. I'm still not taking advantage of some of them as much as I would like, but that's golf and we're always going to say that." Thomas was at 17-under 199 and will be in the final group Sunday with Scheffler, who is trying to end his spectacular season with a ninth title. Tom Kim put himself in the mix, which he might not have imagined Thursday when he was 3 over through six holes of the holiday tournament. Kim got back in the game with a 65 on Friday, and then followed with 12 birdies for a 62. He had a shot at the course record — Rickie Fowler shot 61 in the final round when he won at Albany in 2017 — until Kim found a bunker and took two shots to reach the green in making a double bogey on the par-3 17th. Even so, he was only two shots behind. Ryder Cup captain Keegan Bradley (68) was four back. "Feel like I've been seeing signs of improvement, which is what you want and that's all I can do," Thomas said. "I can't control everybody else or what's going on, I've just got to keep playing as good as I possibly can and hope that it's enough come Sunday."Disability ministers will ‘champion’ inclusion and accessibility, says Timms

Did Matt Gaetz resign from Congress? What to know after he backs out of Trump's AG roleApplied Optoelectronics Stock Slides To 4-Week Low After Downgrade, Flagging Revenue Risk: Retail BearishMatt Gaetz's new gig as right-wing TV show host makes total senseFlorida State continues torrid star with rout of UMass

The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF , an industry benchmark, is up 9% this year compared to 28% for the S&P 500 . Will that trend continue in 2025? It's hard to say, but many individual biotech stocks still look like solid long-term picks. That includes CRISPR Therapeutics ( CRSP 5.70% ) and Exelixis ( EXEL -0.61% ) . The former is well in the red for the year, while the latter has crushed the broader market this year. Despite moving in opposite directions in 2024, CRISPR Therapeutics and Exelixis have strong prospects. Read on to learn more. XBI Total Return Level data by YCharts 1. CRISPR Therapeutics CRISPR Therapeutics is a gene-editing specialist with a major claim to fame: It created Casgevy, the first approved medicine that uses the Nobel prize-winning CRISPR technique. The company developed this therapy with the help of Vertex Pharmaceuticals . Casgevy's first approval came down in November 2023, but CRISPR Therapeutics' shares have underperformed the market since. What gives? First, Casgevy has yet to contribute a single dollar in sales to the biotech due to the complexity of administering gene editing therapies. Second, CRISPR Therapeutics remains unprofitable. That's not unusual for a biotech company of this size, but investors have been less forgiving of unprofitable companies in recent years. Despite these issues, CRISPR Therapeutics looks like an attractive stock. Consider Casgevy's potential. The medicine treats two rare blood-related disorders: transfusion-dependent beta-thalassemia (TDT) and sickle cell disease (SCD). There are few treatment options for either. CRISPR Therapeutics has little competition to speak of in the U.S. and virtually none in other regions such as Europe, Saudi Arabia, and Bahrain. Their target market is about 58,000 patients. Assuming they can treat 20,000 patients at an average price of $1.5 million, it could be a $30 billion opportunity. Casgevy will cost $2.2 million in the U.S., but we don't know its price tag in other countries. At any rate, the medicine has massive potential even before we consider potential label expansions. And it could just be the beginning for CRISPR Therapeutics. Despite Casgevy's slow uptake, the biotech isn't lacking in funds, thanks to its partnership with Vertex Pharmaceuticals. CRISPR Therapeutics ended the third quarter with $1.9 billion in cash and equivalents and several exciting phase 1 and phase 2 gene editing candidates. It won't happen overnight, but between Casgevy's contributions and CRISPR Therapeutics' innovative abilities and exciting pipeline, which will almost certainly land clinical wins in the coming years, the company can rebound from its terrible performance this year. That's why CRISPR Therapeutics is worth investing in now. 2. Exelixis There is one major reason behind Exelixis' strong performance this year. The company earned an important regulatory win that will keep generic competition for its cancer medicine Cabometyx off the market until 2030. Cabometyx, which treats forms of liver and kidney disease, is Exelixis' most important product. The treatment has proven to be a pipeline in a drug, constantly grinding out new indications while remaining the top-prescribed therapy of its kind in some of its markets. This formula, it seems, will continue to work. Exelixis is awaiting more label expansions for its crown jewel, including treatment of pancreatic neuroendocrine tumors (pNET). Cabometyx performed so well in a phase 3 study in pNET patients that, following an interim analysis, an independent monitoring board recommended that the trial be stopped early. It looks very likely that the medicine will earn yet another key label expansion. Meanwhile, Exelixis' financial results remain strong. The company's third-quarter revenue increased by 14% year over year to $539.5 million. Exelixis' adjusted earnings per share of $0.47 was much higher than the $0.10 reported in the year-ago period. Cabometyx should continue driving steady top-line growth for a while. Further, Exelixis is developing other cancer medicines. It is running several phase 3 studies for zanzalintinib, a product it hopes will follow in the footsteps of Cabometyx. Exelixis has several early-stage programs, too. The company's shares might have soared this year, but there is still plenty of upside potential for investors who invest in it today, sit tight, and hold onto the stock for a while.

NoneNEW YORK (AP) — U.S. stocks drifted to a mixed close, as gains for tech stocks nudged the S&P 500 and the Nasdaq to more records. The S&P 500 eked out a gain of under 0.1% Tuesday, while the Nasdaq composite rose 0.4%. The Dow Jones Industrial Average fell 0.2%. Treasury yields held relatively steady after a report showed U.S. employers were advertising slightly more job openings at the end of October than a month earlier. The value of the South Korean won sank against the dollar after its president declared martial law and then later said he’ll lift it. THIS IS A BREAKING NEWS UPDATE. AP’s earlier story follows below. NEW YORK (AP) — U.S. stocks are drifting around their records on Tuesday as Wall Street's white-hot rally lets off the accelerator. The S&P 500 was virtually flat in afternoon trading, a day after rising tech stocks helped it set an all-time high for the 54th time this year. It's climbed in nine of the last 10 days and is on track for one of its best years since the turn of the millennium. The Dow Jones Industrial Average was down by 56 points, or 0.1%, with 45 minutes remaining in trading, while the Nasdaq composite added 0.2% to its own record set a day earlier. AT&T rose 3.9% after it boosted its profit forecast for the year. It also announced a $10 billion plan to send cash to its investors by buying back its own stock, while saying it expects to authorize another $10 billion of repurchases in 2027. On the losing end of Wall Street was U.S. Steel, which fell 7.9%. President-elect Donald Trump reiterated on social media that he would not let Japan’s Nippon Steel take over the iconic Pennsylvania steelmaker. Nippon Steel announced plans last December to buy the Pittsburgh-based steel producer for $14.1 billion in cash, raising concerns about what the transaction could mean for unionized workers, supply chains and U.S. national security. Earlier this year, President Joe Biden also came out against the acquisition. Tesla s sank 2.1% after a judge in Delaware reaffirmed a previous ruling that the electric car maker must revoke Elon Musk’s multibillion-dollar pay package. The judge denied a request by attorneys for Musk and Tesla’s corporate directors to vacate her ruling earlier this year requiring the company to rescind the unprecedented pay package. In the bond market, Treasury yields held relatively steady after a report showed U.S. employers were advertising slightly more job openings at the end of October than a month earlier. Continued strength there would raise optimism that the economy could keep avoiding a recession that many investors had earlier thought was inevitable. The yield on the 10-year Treasury rose to 4.22 from 4.20% from late Monday. Yields have seesawed since Election Day amid worries that Trump's preferences for lower tax rates and bigger tariffs could spur higher inflation along with economic growth. But traders are still confident the Federal Reserve will cut its main interest rate again at its next meeting in two weeks. They’re betting on a nearly three-in-four chance of that, according to data from CME Group. Lower rates can help give the economy more juice, but they can also give inflation more fuel. The key report this week that could guide the Fed’s next move will arrive on Friday. It’s the monthly jobs report , which will show how many workers U.S. employers hired and fired during November. It could be difficult to parse given how much storms and strikes distorted figures in October. Based on trading in the options market, Friday's jobs report appears to be the biggest potential market mover until the Fed announces its next decision on interest rates Dec. 18, according to strategists at Barclays Capital. Since his victory, Trump has broadcasted his plans for tariffs , including for goods coming from China . Trade relations between the U.S. and China took another step backward after China said it is banning exports to the U.S. of gallium, germanium, antimony and other key high-tech materials with potential military applications. The counterpunch came swiftly after the U.S. Commerce Department expanded the list of Chinese technology companies subject to export controls to include many that make equipment used to make computer chips, chipmaking tools and software. The 140 companies newly included in the so-called “entity list” are nearly all based in China. In financial markets abroad, the value of South Korea's currency fell 0.9% against the U.S. dollar following a frenetic night where President Yoon Suk Yeol declared martial law and then later said he'd lift it after lawmakers voted to reject military rule. Stocks of Korean companies that trade in the United States also fell, including a 1.3% drop for SK Telecom. Japan’s Nikkei 225 jumped 1.9% to help lead global markets. Some analysts think Japanese stocks could end up benefiting from Trump’s threats to raise tariffs on China and other countries. Indexes rose 1% in Hong Kong and 0.4% in Shanghai amid unconfirmed reports that Chinese leaders would meet next week to discuss planning for the coming year. Investors are hoping it may bring fresh stimulus to help spur growth in the world’s second-largest economy. In France, the CAC 40 rose 0.3% amid continued worries about politics in Paris , where the government is battling over the budget. ___ AP Business Writers Yuri Kageyama and Matt Ott contributed. Stan Choe, The Associated PressThe Latest: UnitedHealthcare shooting suspect contests his extradition back to New York